Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-23T11:57:25.419Z Has data issue: false hasContentIssue false

Adjunctive memantine in clozapine-treated refractory schizophrenia: A one-year extension study

Published online by Cambridge University Press:  23 March 2020

S. Veerman*
Affiliation:
Mental Health Service Organisation North Holland North, Community Mental Health Division, Flexible Assertive Community Treatment, Alkmaar, Netherlands
P. Schulte
Affiliation:
Mental Health Service Organisation North Holland North, Division for Specialised Treatment, Treatment Centre for Bipolar Disorders, Alkmaar, Netherlands
J.B. Deijen
Affiliation:
VU Medical Center, Psychology, Amsterdam, Netherlands
L. de Haan
Affiliation:
Academic Medical Center, University of Amsterdam, Academic Psychiatric Centre, Early Psychosis Department, Arkin, Amsterdam, Netherlands
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

In a recent 26-week placebo-controlled, crossover trial (n = 52) we found significant positive effects on verbal and visual memory, and negative symptoms in clozapine-treated patients with refractory schizophrenia.

Objectives

In this 1-year extension study, we report the long-term effects and tolerability of memantine add-on therapy to clozapine.

Aims

To evaluate the persistence of improvements in cognitive functioning and symptoms of memantine add-on therapy to clozapine in schizophrenia.

Methods

Completers of the first trial who experienced a beneficial effect of memantine after 12 weeks continued memantine for one year. Primary endpoints were change from baseline to 26 weeks treatment and 26 weeks to 52 weeks treatment on memory and executive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB), Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression Severity Scale (CGI-S). Secondary endpoints were change on the Health of the Nation Outcome Scales (HoNOS) and Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS).

Results

Of 32 completers who experienced a beneficial effect of memantine 23 patients continued memantine for one year. Memory improvement was sustained, verbal recognition memory improved even further between t = 26 weeks and t = 52 weeks. Continued treatment with memantine add-on to clozapine was associated with significantly improved PANSS positive, negative and overall score, CGI-S and HoNOS scores.

Conclusions

In the extension phase the positive effect of memantine add-on therapy on verbal memory sustained and positive, negative and overall symptoms of schizophrenia, clinical global status and psychosocial functioning significantly improved. Memantine was well tolerated without serious adverse effects.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
FC94
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.